The estimated Net Worth of Discovery Technologies Ltd ... is at least $139 Milion dollars as of 18 January 2015. Discovery Ltd owns over 10,208,333 units of Curis Inc stock worth over $139,375,166 and over the last 10 years Discovery sold CRIS stock worth over $0.
Discovery has made over 1 trades of the Curis Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Discovery bought 10,208,333 units of CRIS stock worth $24,499,999 on 18 January 2015.
The largest trade Discovery's ever made was buying 10,208,333 units of Curis Inc stock on 18 January 2015 worth over $24,499,999. On average, Discovery trades about 10,208,333 units every 0 days since 2015. As of 18 January 2015 Discovery still owns at least 27,328,464 units of Curis Inc stock.
You can see the complete history of Discovery Ltd stock trades at the bottom of the page.
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ... oraz James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: